Short DNA/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencing

Antisense oligonucleotide (ASO)-based therapy is one of the next-generation therapy, especially targeting neurological disorders. Many cases of ASO-dependent gene expression suppression have been reported. Recently, we developed a tocopherol conjugated DNA/RNA heteroduplex oligonucleotide (Toc-HDO)...

Descripción completa

Detalles Bibliográficos
Autores principales: Asada, Ken, Sakaue, Fumika, Nagata, Tetsuya, Zhang, Ji-chun, Yoshida-Tanaka, Kie, Abe, Aya, Nawa, Makiko, Nishina, Kazutaka, Yokota, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Chemical Biology and Nucleic Acid Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136785/
https://www.ncbi.nlm.nih.gov/pubmed/33928345
http://dx.doi.org/10.1093/nar/gkab258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136785/
https://www.ncbi.nlm.nih.gov/pubmed/33928345
http://dx.doi.org/10.1093/nar/gkab258

Ejemplares similares